Extending incentives for rare pediatric disease treatments until 2030.
This Act extends the program that provides incentives to pharmaceutical companies developing treatments for rare pediatric diseases. Companies receive Priority Review Vouchers, which speed up the approval process for other drugs, encouraging investment in challenging pediatric research. Extending this authority until September 2030 increases the likelihood of new, life-saving therapies becoming available for children.
Key points
Extends the authority to issue Priority Review Vouchers until September 30, 2030.
The goal is to encourage drug development for rare pediatric diseases.
Impact on citizens: potentially faster access to innovative treatments for children suffering from rare conditions.
Expired
Citizen Poll